{
    "clinical_study": {
        "@rank": "62283", 
        "brief_summary": {
            "textblock": "To examine the effectiveness of subcutaneous gamma interferon in reducing severity of\n      Mycobacterium avium- intracellulare (MAI) bacillemia episodes in AIDS patients in an\n      open-label dose-randomized multi-center pilot clinical investigation. To evaluate the safety\n      of gamma interferon given by subcutaneous injection (SC) in the AIDS patient in the presence\n      and absence of AZT therapy."
        }, 
        "brief_title": "Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study", 
        "condition": [
            "Mycobacterium Avium-Intracellulare Infection", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Mycobacterium Infections", 
                "Mycobacterium avium-intracellulare Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Diagnosis of AIDS and persistent Mycobacterium avium- intracellulare (MAI)\n             bacillemia.\n\n          -  Life expectancy of at least 3 months.\n\n          -  Baseline chest X-ray and EKG (electrocardiogram).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Known hypersensitivity to interferons or other exogenous lymphokine.\n\n          -  History of cardiac abnormality or disease.\n\n          -  History of hypertension.\n\n        Patients with the following are excluded:\n\n          -  Known hypersensitivity to interferons or other exogenous lymphokine.\n\n          -  History of cardiac abnormality or disease.\n\n          -  History of hypertension.\n\n        Prior Medication:\n\n        Excluded within 4 weeks of study entry:\n\n          -  Corticosteroids.\n\n          -  Anti-inflammatory medication (except aspirin).\n\n          -  Changes in the dose of anti-mycobacterial drugs.\n\n          -  Immune agents.\n\n        Prior Treatment:\n\n        Excluded within 4 weeks of study entry:\n\n          -  Radiotherapy.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Intravenous drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "15", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002037", 
            "org_study_id": "062B", 
            "secondary_id": "IFNG-8701"
        }, 
        "intervention": {
            "intervention_name": "Trifluridine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Trifluridine"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Mycobacterium avium-intracellulare Infection", 
            "Interferon-gamma, Recombinant", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "New York Hosp - Cornell Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002037"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1991"
    }, 
    "geocoordinates": {
        "New York Hosp - Cornell Med Ctr": "40.714 -74.006"
    }
}